Quantum Cyber N.V. Employee Benefits Expense
Quantum Cyber N.V. (QUCY) reported Employee Benefits Expense of $21.29 thousand for the 6-month period ending 2024-06-30, per its 6-K filed 2024-10-18.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:EmployeeBenefitsExpense · last filed 2024-10-18
- Quantum Cyber N.V. employee benefits expense for the quarter ending 2023-12-31 was $1.02M, a 23.84% increase year-over-year.
- Quantum Cyber N.V. employee benefits expense for the quarter ending 2023-09-30 was $613.03K.
- Quantum Cyber N.V. employee benefits expense for the quarter ending 2023-06-30 was -$372.44K, a 136.33% decline year-over-year.
- Quantum Cyber N.V. employee benefits expense for the quarter ending 2023-03-31 was $387.40K, a 62.15% increase year-over-year.
| Period end | Employee Benefits Expense 3 month | Employee Benefits Expense 6 month | Employee Benefits Expense 6 month as first filed | Employee Benefits Expense 9 month | Employee Benefits Expense 12 month |
|---|---|---|---|---|---|
| 2024-06-30 | $21.29K 6-K · filed 2024-10-18 | ||||
| 2023-12-31 | $1.02M derived: 20-F 12 month − 6-K 9 month · filed 2024-04-09 | $1.63M derived: sum of 2 quarters · filed 2024-04-09 | $1.26M derived: sum of 3 quarters · filed 2024-10-18 | $1.65M 20-F · filed 2024-04-09 | |
| 2023-09-30 | $613.03K derived: 6-K 9 month − 6-K 6 month · filed 2023-11-16 | $240.59K derived: sum of 2 quarters · filed 2024-10-18 | $627.99K 6-K · filed 2023-11-16 | $1.45M derived: sum of 4 quarters · filed 2024-10-18 | |
| 2023-06-30 | -$372.44K derived: 6-K 6 month − 6-K 3 month · filed 2024-10-18 | $14.96K 6-K · filed 2024-10-18 | $921.49K 6-K · filed 2023-08-15 | $837.96K derived: sum of 3 quarters · filed 2024-10-18 | $41.83K derived: sum of 4 quarters · filed 2024-10-18 |
| 2023-03-31 | $387.40K 6-K · filed 2023-05-16 | $1.21M derived: sum of 2 quarters · filed 2024-04-09 | $414.27K derived: sum of 3 quarters · filed 2024-04-09 | $1.44M derived: sum of 4 quarters · filed 2024-04-09 | |
| 2022-12-31 | $823.01K derived: 20-F 12 month − 6-K 9 month · filed 2024-04-09 | $26.87K derived: sum of 2 quarters · filed 2024-04-09 | $1.05M derived: sum of 3 quarters · filed 2024-04-09 | $1.29M 20-F · filed 2024-04-09 | |
| 2022-09-30 | -$796.14K derived: 6-K 9 month − 6-K 6 month · filed 2023-11-16 | $229.14K derived: sum of 2 quarters · filed 2023-11-16 | $468.05K 6-K · filed 2023-11-16 | ||
| 2022-06-30 | $1.03M derived: 6-K 6 month − 6-K 3 month · filed 2023-08-15 | $1.26M 6-K · filed 2023-08-15 | |||
| 2022-03-31 | $238.91K 6-K · filed 2023-05-16 | ||||
| 2021-12-31 | $673.46K 20-F · filed 2024-04-09 | ||||
| 2021-06-30 | $109.73K 6-K · filed 2022-09-07 | ||||
| 2020-12-31 | $202.44K 20-F · filed 2023-04-07 | ||||
| 2019-12-31 | $192.42K 20-F · filed 2022-05-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |